Last May, a controversial paper in the New England Journal of Medicine (NEJM) reported that a popular diabetes drug—rosiglitazone, sold under the brand name Avandia—substantially hikes a user's risk of heart attack.
But according to an ongoing investigation by the U.S. Senate Committee on Finance, Avandia's maker, the Philadelphia-based GlaxoSmithKline, knew about the study before it was published.
The company was in possession of a leaked copy, courtesy of a scientist that NEJM had recruited for a peer review of the paper.
Read more at Science News Online
No comments:
Post a Comment